Measles Vaccination in the Presence or Absence of Maternal Measles Antibody: Impact on Child Survival

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2014 May 16

PMID 24829213

Citations 32

Authors

Peter Aaby

Cesario L Martins

May-Lill Garly

Andreas Andersen

Ane B Fisker

Mogens H Claesson

Henrik Ravn

Amabelia Rodrigues

Hilton C Whittle

Christine S Benn

Affiliations

Soon will be listed here.

Abstract

Background: Measles vaccine (MV) has a greater effect on child survival when administered in early infancy, when maternal antibody may still be present.

Methods: To test whether MV has a greater effect on overall survival if given in the presence of maternal measles antibody, we reanalyzed data from 2 previously published randomized trials of a 2-dose schedule with MV given at 4-6 months and at 9 months of age. In both trials antibody levels had been measured before early measles vaccination.

Results: In trial I (1993-1995), the mortality rate was 0.0 per 1000 person-years among children vaccinated with MV in the presence of maternal antibody and 32.3 per 1000 person-years without maternal antibody (mortality rate ratio [MRR], 0.0; 95% confidence interval [CI], 0-.52). In trial II (2003-2007), the mortality rate was 4.2 per 1000 person-years among children vaccinated in presence of maternal measles antibody and 14.5 per 1000 person-years without measles antibody (MRR, 0.29; 95% CI, .09-.91). Possible confounding factors did not explain the difference. In a combined analysis, children who had measles antibody detected when they received their first dose of MV at 4-6 months of age had lower mortality than children with no maternal antibody, the MRR being 0.22 (95% CI, .07-.64) between 4-6 months and 5 years.

Conclusions: Child mortality in low-income countries may be reduced by vaccinating against measles in the presence of maternal antibody, using a 2-dose schedule with the first dose at 4-6 months (earlier than currently recommended) and a booster dose at 9-12 months of age.

Clinical Trials Registration: NCT00168558.

Citing Articles

Bacille Calmette-Guérin-specific IgG titres among infants born to mothers with active tuberculosis disease in Uganda.

Sitenda D, Ssekamatte P, Nakavuma R, Kyazze A, Bongomin F, Baluku J BMC Immunol. 2025; 26(1):13.

PMID: 40038578 PMC: 11877890. DOI: 10.1186/s12865-025-00692-w.

Prenatal Maternal Immunization for Infant Protection: A Review of the Vaccines Recommended, Infant Immunity and Future Research Directions.

Quincer E, Cranmer L, Kamidani S Pathogens. 2024; 13(3).

PMID: 38535543 PMC: 10975994. DOI: 10.3390/pathogens13030200.

Measles, mumps, and rubella vaccine at age 6 months and hospitalisation for infection before age 12 months: randomised controlled trial.

Zimakoff A, Jensen A, Vittrup D, Herlufsen E, Sorensen J, Malon M BMJ. 2023; 381:e072724.

PMID: 37286215 PMC: 10245144. DOI: 10.1136/bmj-2022-072724.

Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine.

Cheung F, Apps R, Dropulic L, Kotliarov Y, Chen J, Jordan T Elife. 2023; 12.

PMID: 36648132 PMC: 9844983. DOI: 10.7554/eLife.80652.

Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections.

Aaby P, Netea M, Benn C Lancet Infect Dis. 2022; 23(1):e34-e42.

PMID: 36037824 PMC: 9417283. DOI: 10.1016/S1473-3099(22)00498-4.

References

Shann F . The non-specific effects of vaccines. Arch Dis Child. 2010; 95(9):662-7. DOI: 10.1136/adc.2009.157537. View

POULSEN A, Kvinesdal B, Aaby P, Molbak K, Frederiksen K, Dias F . Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet. 1989; 1(8642):827-31. DOI: 10.1016/s0140-6736(89)92281-2. View

de Quadros C, Izurieta H, Venczel L, Carrasco P . Measles eradication in the Americas: progress to date. J Infect Dis. 2004; 189 Suppl 1:S227-35. DOI: 10.1086/377741. View

Sorup S, Benn C, Poulsen A, Krause T, Aaby P, Ravn H . Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA. 2014; 311(8):826-35. DOI: 10.1001/jama.2014.470. View

Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J . Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis. 2001; 184(7):817-26. DOI: 10.1086/323346. View

Benn C, Balde A, George E, Kidd M, Whittle H, Lisse I . Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. Lancet. 2002; 359(9314):1313-4. DOI: 10.1016/S0140-6736(02)08274-0. View

Aaby P, Jensen H, Samb B, Cisse B, Sodemann M, Jakobsen M . Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet. 2003; 361(9376):2183-8. DOI: 10.1016/S0140-6736(03)13771-3. View

Koenig M, Khan M, Wojtyniak B, Clemens J, Chakraborty J, Fauveau V . Impact of measles vaccination on childhood mortality in rural Bangladesh. Bull World Health Organ. 1990; 68(4):441-7. PMC: 2393147. View

Navarini A, Krzyzowska M, Lang K, Horvath E, Hengartner H, Niemialtowski M . Long-lasting immunity by early infection of maternal-antibody-protected infants. Eur J Immunol. 2009; 40(1):113-6. DOI: 10.1002/eji.200939371. View

10.

Martins C, Benn C, Andersen A, Bale C, Schaltz-Buchholzer F, Do V . A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J Infect Dis. 2014; 209(11):1731-8. PMC: 4017359. DOI: 10.1093/infdis/jit804. View

11.

Aaby P, Andersen M, Knudsen K . Excess mortality after early exposure to measles. Int J Epidemiol. 1993; 22(1):156-62. DOI: 10.1093/ije/22.1.156. View

12.

Aaby P, Samb B, Simondon F, Seck A, Knudsen K, Whittle H . Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ. 1995; 311(7003):481-5. PMC: 2550544. DOI: 10.1136/bmj.311.7003.481. View

13.

Lemke H, Coutinho A, Lange H . Lamarckian inheritance by somatically acquired maternal IgG phenotypes. Trends Immunol. 2004; 25(4):180-6. DOI: 10.1016/j.it.2004.02.007. View

14.

Shann F . Heterologous immunity and the nonspecific effects of vaccines: a major medical advance?. Pediatr Infect Dis J. 2004; 23(6):555-8. DOI: 10.1097/01.inf.0000130155.42392.04. View

15.

Aaby P, Bhuiya A, Nahar L, Knudsen K, De Francisco A, Strong M . The survival benefit of measles immunization may not be explained entirely by the prevention of measles disease: a community study from rural Bangladesh. Int J Epidemiol. 2003; 32(1):106-16. DOI: 10.1093/ije/dyg005. View

16.

Aaby P, Martins C, Garly M, Rodrigues A, Benn C, Whittle H . The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy. BMJ Open. 2012; 2(4). PMC: 3401826. DOI: 10.1136/bmjopen-2011-000761. View

17.

Aaby P, Lisse I, Whittle H, Knudsen K, Thaarup J, Poulsen A . Long-term survival in trial of medium-titre Edmonston-Zagreb measles vaccine in Guinea-Bissau: five-year follow-up. Epidemiol Infect. 1994; 112(2):413-20. PMC: 2271462. DOI: 10.1017/s0950268800057836. View

18.

Benn C, Netea M, Selin L, Aaby P . A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013; 34(9):431-9. DOI: 10.1016/j.it.2013.04.004. View

19.

Benn C, Aaby P, Bale C, Olsen J, Michaelsen K, George E . Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. Lancet. 1997; 350(9071):101-5. DOI: 10.1016/S0140-6736(96)12019-5. View

20.

Aaby P, Bukh J, Kronborg D, Lisse I, da Silva M . Delayed excess mortality after exposure to measles during the first six months of life. Am J Epidemiol. 1990; 132(2):211-9. DOI: 10.1093/oxfordjournals.aje.a115650. View